Browse FOXC2

Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00250 Forkhead domain
Function

Transcriptional activator. Might be involved in the formation of special mesenchymal tissues.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001525 angiogenesis
GO:0001569 patterning of blood vessels
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001657 ureteric bud development
GO:0001667 ameboidal-type cell migration
GO:0001704 formation of primary germ layer
GO:0001707 mesoderm formation
GO:0001710 mesodermal cell fate commitment
GO:0001756 somitogenesis
GO:0001763 morphogenesis of a branching structure
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0001945 lymph vessel development
GO:0001946 lymphangiogenesis
GO:0001974 blood vessel remodeling
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0002064 epithelial cell development
GO:0003002 regionalization
GO:0003007 heart morphogenesis
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0003151 outflow tract morphogenesis
GO:0003158 endothelium development
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003229 ventricular cardiac muscle tissue development
GO:0003231 cardiac ventricle development
GO:0003275 apoptotic process involved in outflow tract morphogenesis
GO:0003278 apoptotic process involved in heart morphogenesis
GO:0007219 Notch signaling pathway
GO:0007369 gastrulation
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007498 mesoderm development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0008015 blood circulation
GO:0008286 insulin receptor signaling pathway
GO:0009952 anterior/posterior pattern specification
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0014706 striated muscle tissue development
GO:0014855 striated muscle cell proliferation
GO:0030198 extracellular matrix organization
GO:0030199 collagen fibril organization
GO:0030335 positive regulation of cell migration
GO:0032835 glomerulus development
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0033002 muscle cell proliferation
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0033630 positive regulation of cell adhesion mediated by integrin
GO:0035050 embryonic heart tube development
GO:0035150 regulation of tube size
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0035282 segmentation
GO:0035470 positive regulation of vascular wound healing
GO:0035850 epithelial cell differentiation involved in kidney development
GO:0036303 lymph vessel morphogenesis
GO:0040017 positive regulation of locomotion
GO:0043010 camera-type eye development
GO:0043062 extracellular structure organization
GO:0043434 response to peptide hormone
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043536 positive regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0045165 cell fate commitment
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045785 positive regulation of cell adhesion
GO:0046620 regulation of organ growth
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048332 mesoderm morphogenesis
GO:0048333 mesodermal cell differentiation
GO:0048339 paraxial mesoderm development
GO:0048340 paraxial mesoderm morphogenesis
GO:0048341 paraxial mesoderm formation
GO:0048342 paraxial mesodermal cell differentiation
GO:0048343 paraxial mesodermal cell fate commitment
GO:0048514 blood vessel morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048638 regulation of developmental growth
GO:0048644 muscle organ morphogenesis
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048703 embryonic viscerocranium morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048738 cardiac muscle tissue development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048762 mesenchymal cell differentiation
GO:0048771 tissue remodeling
GO:0048844 artery morphogenesis
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0050880 regulation of blood vessel size
GO:0051272 positive regulation of cellular component movement
GO:0055008 cardiac muscle tissue morphogenesis
GO:0055010 ventricular cardiac muscle tissue morphogenesis
GO:0055017 cardiac muscle tissue growth
GO:0060038 cardiac muscle cell proliferation
GO:0060055 angiogenesis involved in wound healing
GO:0060415 muscle tissue morphogenesis
GO:0060419 heart growth
GO:0060485 mesenchyme development
GO:0060537 muscle tissue development
GO:0060561 apoptotic process involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060795 cell fate commitment involved in formation of primary germ layer
GO:0060840 artery development
GO:0061005 cell differentiation involved in kidney development
GO:0061041 regulation of wound healing
GO:0061042 vascular wound healing
GO:0061043 regulation of vascular wound healing
GO:0061053 somite development
GO:0061138 morphogenesis of a branching epithelium
GO:0061318 renal filtration cell differentiation
GO:0061437 renal system vasculature development
GO:0061440 kidney vasculature development
GO:0061448 connective tissue development
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072007 mesangial cell differentiation
GO:0072008 glomerular mesangial cell differentiation
GO:0072009 nephron epithelium development
GO:0072010 glomerular epithelium development
GO:0072011 glomerular endothelium development
GO:0072012 glomerulus vasculature development
GO:0072073 kidney epithelium development
GO:0072109 glomerular mesangium development
GO:0072112 glomerular visceral epithelial cell differentiation
GO:0072132 mesenchyme morphogenesis
GO:0072143 mesangial cell development
GO:0072144 glomerular mesangial cell development
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072311 glomerular epithelial cell differentiation
GO:0090049 regulation of cell migration involved in sprouting angiogenesis
GO:0090050 positive regulation of cell migration involved in sprouting angiogenesis
GO:0090066 regulation of anatomical structure size
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090303 positive regulation of wound healing
GO:1901342 regulation of vasculature development
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902256 regulation of apoptotic process involved in outflow tract morphogenesis
GO:1902257 negative regulation of apoptotic process involved in outflow tract morphogenesis
GO:1902337 regulation of apoptotic process involved in morphogenesis
GO:1902338 negative regulation of apoptotic process involved in morphogenesis
GO:1902742 apoptotic process involved in development
GO:1903034 regulation of response to wounding
GO:1903036 positive regulation of response to wounding
GO:1903670 regulation of sprouting angiogenesis
GO:1903672 positive regulation of sprouting angiogenesis
GO:1904018 positive regulation of vasculature development
GO:1904238 pericyte cell differentiation
GO:1904746 negative regulation of apoptotic process involved in development
GO:1904748 regulation of apoptotic process involved in development
GO:1904888 cranial skeletal system development
GO:2000027 regulation of organ morphogenesis
GO:2000147 positive regulation of cell motility
GO:2000826 regulation of heart morphogenesis
Molecular Function GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0031490 chromatin DNA binding
GO:0043566 structure-specific DNA binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FOXC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FOXC2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FOXC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1360.000989
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3740.0253
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9660.064
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1650.783
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2150.847
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0960.938
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1080.83
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2610.819
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0910.941
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4010.588
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3710.703
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.970.000395
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FOXC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOXC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOXC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOXC2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOXC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FOXC2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FOXC2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFOXC2
Nameforkhead box C2
Aliases MFH-1; mesenchyme forkhead 1; FKHL14; forkhead box C2 (MFH-1, mesenchyme forkhead 1); MFH1; MFH-1,mesenchyme ......
Chromosomal Location16q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FOXC2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.